Crescita Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Crescita Therapeutics generated cash of $2,076,000, which is more than the previous year. Cash used in financing activities reached the amount of -$782,000 last year. Net change in cash is therefore $1,147,000.
Cash Flow
| 2014 | -9.29M | -43K | 9.10M |
|---|---|---|---|
| 2015 | -13.91M | -23K | 13.94M |
| 2016 | -18.57M | -11.41M | 39.58M |
| 2017 | -7.40M | 7.74M | -3.15M |
| 2018 | -1.47M | -144K | 3.18M |
| 2019 | 5.30M | -215K | -4.39M |
| 2020 | 5.60M | -59K | -476K |
| 2021 | -1.59M | -846K | -500K |
| 2022 | -1.02M | -290K | -1.84M |
| 2023 | 2.07M | -133K | -782K |
CTX.TO Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 8.23M | 11.33M | 14.28M | 9.26M | 8.58M | 6.99M | 9.80M | 478K | 443K | 621K |
Operating activities | ||||||||||
Net income | -1.98M | 862K | -1.10M | 37K | 1.85M | 2.39M | -11.46M | -12.70M | -15.44M | -14.60M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.50M | 1.47M | 1.37M | 1.49M | 1.72M | 1.14M | 1.16M | 418K | 37K | 300K |
Stock-based compensation expense | 82K | 221K | 272K | 155K | 287K | 0 | 251K | 177K | 121K | 245K |
| Deferred income tax benefit | 82K | 221K | 272K | 155K | 287K | 0 | 251K | 177K | 121K | 245K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 3.53M | -2.57M | -1.04M | 1.24M | 2.80M | -3.88M | 206K | -508K | 75K | 2.22M |
Inventories | -917K | -1.78M | -1.37M | -41K | -1.33M | 318K | -986K | 460K | -66K | -108K |
Accounts payable | -1.28M | 232K | 993K | 332K | 163K | 0 | -2.56M | 0 | 773K | 0 |
Cash generated by operating activities | 2.07M | -1.02M | -1.59M | 5.60M | 5.30M | -1.47M | -7.40M | -18.57M | -13.91M | -9.29M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -8.55M | 0 | 0 |
Investments In Property Plant And Equipment | -133K | -229K | -346K | -59K | -215K | -144K | -107K | -123K | -23K | -43K |
Acquisitions Net | 0 | -61K | 0 | 0 | 0 | 0 | -700K | -2.74M | 0 | 0 |
Cash generated by investing activities | -133K | -290K | -846K | -59K | -215K | -144K | 7.74M | -11.41M | -23K | -43K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 0 | 0 | 0 | 3.52M | 25K | 0 | 14.12M | 9.27M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -393K | -429K | -101K | -68K | -257K | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -408K | -1.37M | -349K | -358K | -3.88M | 0 | -2.18M | -280K | 0 | -166K |
Cash used in financing activities | -782K | -1.84M | -500K | -476K | -4.39M | 3.18M | -3.15M | 39.58M | 13.94M | 9.10M |
Net Change In Cash | 1.14M | -3.09M | -2.95M | 5.01M | 679K | 1.59M | -2.81M | 9.32M | 35K | -178K |
Cash at end of period | 9.38M | 8.23M | 11.33M | 14.28M | 9.26M | 8.58M | 6.99M | 9.80M | 478K | 443K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |